Trulicity (dulaglutide) side effects: the weekly diabetes GLP-1

Across the AWARD trial program, nausea led at roughly 12 to 21% depending on dose, with diarrhea, vomiting, and abdominal pain following, plus reduced appetite and occasional dyspepsia. The overwhelming majority were mild to moderate, concentrated in the first weeks and around the single dose increase, and settling with adaptation.

Injection-site reactions are notably low for dulaglutide, an advantage often credited to the auto-injector and formulation. As with the class, the effects cluster in the days after the weekly dose and ease by mid-week.

Dulaglutide keeps titration simple. A common start is 0.75 mg weekly, stepping to 1.5 mg, with higher 3 mg and 4.5 mg options for additional glucose lowering. Fewer steps than the long weight-management ladders means a simpler, usually gentler adjustment.

The device is the selling point: pre-filled, single-button, needle hidden start to finish. For needle-averse patients this can be the difference between starting treatment and not, and it keeps site complaints low.

Head-to-head, semaglutide (Ozempic) beat dulaglutide on both glucose and weight in the SUSTAIN 7 trial, and tirzepatide outperformed dulaglutide in SURPASS. Dulaglutide is a solid, well-tolerated glucose-first drug with a beloved device, not a weight-loss leader.

Practical translation: if weight loss is the priority, the newer agents average more; if a simple weekly diabetes drug with an easy injector and good tolerability is the goal, dulaglutide earns its long-standing popularity. That is a prescriber conversation weighing glucose targets, weight goals, and device preference.

The class red flags apply unchanged: severe persistent abdominal pain (especially radiating to the back) for pancreatitis, right-sided pain after fatty meals for gallbladder disease, vomiting past 24 hours for dehydration, and allergic reactions with facial swelling or breathing trouble.

Diabetes-specific: hypoglycemia when combined with insulin or a sulfonylurea (know the shakiness-sweating-confusion pattern), prompt attention for sudden vision changes as glucose improves, and the thyroid C-cell contraindication for personal or family history of medullary thyroid carcinoma or MEN2.

Dulaglutide's half-life is about 5 days, so levels stay steady through the week and a missed dose is buffered: the label allows taking it if at least 3 days remain before the next scheduled dose, otherwise skip and resume on schedule, never doubling. After a final dose it clears over roughly 3 to 4 weeks.

As with the class, stopping returns appetite and, for diabetes users, means glucose management shifts back to other tools, a transition to plan with your prescriber rather than an abrupt stop. Logging your dose day, glucose surprises, and side effects keeps that conversation grounded.